查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球頭頸癌治療市場：市場規模、市場份額、趨勢分析、機遇和預測：按類型、治療類型、給藥途徑、最終用戶、地區2018-2028
市場調查報告書
商品編碼
1172560

全球頭頸癌治療市場：市場規模、市場份額、趨勢分析、機遇和預測：按類型、治療類型、給藥途徑、最終用戶、地區2018-2028

Head and Neck Cancer Therapeutics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2018-2028, Segmented By Type ; Treatment Type ; Route of Administration ; By End-User ; Region
出版日期: | 出版商: Blueweave Consulting | 英文 254 Pages | 商品交期: 2-3個工作天內

價格

全球頭頸癌治療市場規模預計將從 2021 年的 11 億美元增長到 2028 年的約 26 億美元，在預測期內以 12.6% 的複合年增長率增長。 生物仿製藥的使用增加、早期診斷和積極的醫療改革正在推動市場增長。

本報告研究了全球頭頸癌治療市場，並提供了全面的信息，包括市場概況、市場分析和公司概況。

內容

第一章研究框架

第 2 章執行摘要

第 3 章全球頭頸癌藥物市場洞察

  • 行業價值鏈分析
  • DROC 分析
    • 司機
      • 增加生物仿製藥的使用
      • 早期診斷方法的興起
      • 積極的醫療改革
    • 約束因素
      • 嚴重的藥物副作用
      • 其他
    • 機會
      • 對頭頸癌聯合療法的需求不斷增加
      • 其他
    • 任務
      • 高昂的治療費用
      • 其他
  • 技術進步/最新發展
  • 監管框架
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭激烈程度

第 4 章全球頭頸癌治療市場概況

  • 市場規模和預測（2018-2028 年）（按價值）
    • 按金額（百萬美元）
  • 市場份額和預測
    • 按類型
      • 診斷
      • 治療
    • 按治療類型
      • 根據指示
    • 按給藥途徑
      • 注射
      • 口語
    • 最終用戶
      • 醫院
      • 專科診所
      • 門診手術中心
      • 其他
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

第五章北美頭頸癌藥物市場

第六章歐洲頭頸癌藥物市場

第7章亞太地區頭頸癌藥物市場

第 8 章. 拉丁美洲的頭頸癌藥物市場

第 9 章中東和非洲頭頸癌藥物市場

第10章競爭格局

  • 主要公司及其產品列表
  • 市場份額分析（2021 年）
  • 競爭基準：按操作參數
  • 重大戰略發展（合併、收購、合作等）

第 11 章 COVID-19 對全球頭頸癌藥物市場的影響

第 12 章公司簡介（公司概況、財務矩陣、競爭格局、關鍵人才、主要競爭對手、聯繫人、SWOT 和戰略展望）**

  • Pfizer INC
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Limited
  • Intas Pharmaceuticals Ltd
  • Glaxosmithkline PLC
  • Novartis International AG
  • Sanofi
  • Bayer AG
  • Hoffmann-LA Roche AG
  • Merck & co., INC
  • Astrazenica PLC
  • Teva Pharmaceutical Industries Ltd.
  • 其他

第 13 章關鍵戰略建議

第 14 章研究方法論

注：對於最終交付成果，除上述公司外的其他公司的財務信息將在數據可用時提供。

在最終可交付成果中，細分和公司可能會隨著詳細的補充信息而發生變化。

Product Code: BWC22576

Global Head and Neck Cancer Therapeutics Market to Grow at a CAGR of 12.6% during Forecast Period.

Global Head and Neck Cancer Therapeutics Market is growing at a high CAGR because of the rising use of biosimilars and early diagnostic methods as well as positive healthcare reforms.

A recent study conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the Global Head and Neck Cancer Therapeutics Market was worth USD 1.1 billion in the year 2021. The market is projected to grow at a CAGR of 12.6% from 2022-2028 (forecast period), earning revenues of around USD 2.6 billion by the end of 2028. The Global Head and Neck Cancer Therapeutics Market is booming because of the rising demand for consumer electronic items like smartphones, televisions, and digital cameras, as well as the increased manufacturing of electric cars. In addition, rising demand for IoT devices is emerging as a significant driver of market expansion. However, high dependence on other countries for semiconductor chip imports may act as a huge restraining factor for market growth.

Increased demand for a combination treatment for head and neck cancer care

Increases in the prevalence of specific diseases and the availability of better healthcare thanks to public and private sector initiatives are all expected to propel the industry forward in the next years. The global market for head and neck cancer treatments is growing as a result of several factors, including the rising incidence of this disease worldwide, the rising preference for multimodal approaches to care, and the rising emphasis on research and development to identify the most effective clinical therapy.

In addition, an increase in risk factors such as alcohol, cigarette smoking, and tobacco use is anticipated to contribute to the growing worldwide need for head and neck cancer treatments.

Challenge

High treatment costs

Market growth is anticipated to be stymied by the high expenses associated with the treatment plan, the unfavorable reactions of alternative treatment alternatives, the dearth of insurance services, and the inadequate healthcare system in low- and middle-income countries. Moreover, this patient population faces major issues, such as morbidity and bad quality of life, as a direct result of the incapacitating impact of normal healthcare practices.

Segmental Coverage

Global Head and Neck Cancer Therapeutics Market - By End-User

On the basis of end-user segmentation, the Global Head and Neck Cancer Therapeutics Market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others. Whereby hospitals and specialty clinics take a sizable amount in market share. Due to simple access to medications and inexpensive distribution costs, producers are very likely to distribute their goods, which explains the dominance. According to the Drug Channels Institute's research, the top five specialty pharmacies in the globe in 2021 were Humana specialty pharmacy, Accredo, CVS Specialty, Walgreens stores, and Optum specialty pharmacy.

Global Head and Neck Cancer Therapeutics Market - By Region

The global market for head and neck cancer therapies is divided into five primary regions based on geographical presence. These regions are North America, Europe, The Asia Pacific, Latin America, the Middle East, and Africa. The high frequency of HPV-induced malignancies and the high smoking rate in North America will continue to provide the region with a dominant position in the worldwide head and neck cancer treatment market. It is anticipated that Europe will hold the second biggest market share in the global market for head and neck cancer therapies.

Impact of COVID-19 on Global Head and Neck Cancer Therapeutics Market

The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) that produced the 2019 coronavirus disease (COVID-19) pandemic poses a unique challenge to the world's healthcare infrastructure, including the Global Head and Neck Cancer Therapeutics Market. Standardized treatment for cancer patients was a part of this difficulty. During this time, most in-hospital cancer treatments were discontinued, and only select patients were given radiation therapy with the goal of curing them in accordance with strict protocols to ensure their safety, thereby leading to disturbances and inconveniences in the Global Head and Neck Cancer Therapeutics Market.

Competitive Landscape

Pfizer Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Ltd., GlaxoSmithKline PLC, Novartis International AG, Sanofi, Bayer AG, Hoffmann-LA Roche AG, Merck & co., INC., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., and Other Prominent Players are active in this industry. AstraZeneca and Pfizer are expected to benefit from the approval of Imfinzi and Bavencio during the projection period. Sanofi and Eli Lilly have been affected by expiring patents and biosimilar medicine competition. Several market participants are expected to collaborate on meeting unmet requirements, discovering novel targets, and developing stronger treatment pipelines.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Head and Neck Cancer Therapeutics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Head and Neck Cancer Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Head and Neck Cancer Therapeutics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising Biosimilar Use
      • 3.2.1.2. Rise in early Diagnostic Methods
      • 3.2.1.3. Positive Healthcare Reforms
    • 3.2.2. Restraints
      • 3.2.2.1. Frequent failure at the end of the process, Substantial medication adverse effects are a fact of life
      • 3.2.2.2. Others
    • 3.2.3. Opportunities
      • 3.2.3.1. Increased demand for a combination treatment for head and neck cancer care
      • 3.2.3.2. Others
    • 3.2.4. Challenges
      • 3.2.4.1. High Treatment Cost
      • 3.2.4.2. Others
  • 3.3. Technological Advancement/Recent Development
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Head and Neck Cancer Therapeutics Market Overview

  • 4.1. Market Size & Forecast by Value, 2018-2028
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Diagnostic Method
      • 4.2.1.1.1. Biopsy
      • 4.2.1.1.2. Imaging
      • 4.2.1.1.3. Endoscopy
      • 4.2.1.1.4. Others
      • 4.2.1.2. Treatment
      • 4.2.1.2.1. Surgery
      • 4.2.1.2.2. Radiation Therapy
      • 4.2.1.2.3. Chemotherapy
      • 4.2.1.2.4. Immunotherapy
      • 4.2.1.2.5. Targeted Therapy
    • 4.2.2. By Treatment Type
      • 4.2.2.1. By Disease Indication
      • 4.2.2.1.1. Lip and Oral Cavity Cancer
      • 4.2.2.1.2. Laryngeal Cancer
      • 4.2.2.1.3. Oropharyngeal Cancer
      • 4.2.2.1.4. Salivary Gland Cancer
      • 4.2.2.1.5. Nasopharyngeal Cancer
      • 4.2.2.1.6. Hypopharyngeal Cancer
    • 4.2.3. By Route of Administration
      • 4.2.3.1. Injectable
      • 4.2.3.2. Oral
    • 4.2.4. By End-User
      • 4.2.4.1. Hospitals
      • 4.2.4.2. Specialty Clinics
      • 4.2.4.3. Ambulatory Surgical Centers
      • 4.2.4.4. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. The Asia Pacific
      • 4.2.5.4. Latin America
      • 4.2.5.5. The Middle East and Africa

5. North America Head and Neck Cancer Therapeutics Market

  • 5.1. Market Size & Forecast by Value, 2018-2028
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Treatment Type
    • 5.2.3. By Route of Administration
    • 5.2.4. By End-User
    • 5.2.5. By Country
      • 5.2.5.1. United Type
      • 5.2.5.2. Canada

6. Europe Head and Neck Cancer Therapeutics Market

  • 6.1. Market Size & Forecast by Value, 2018-2028
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By End-User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.2. United Kingdom
      • 6.2.5.3. Italy
      • 6.2.5.4. France
      • 6.2.5.5. Spain
      • 6.2.5.6. Rest of Europe

7. The Asia Pacific Head and Neck Cancer Therapeutics Market

  • 7.1. Market Size & Forecast by Value, 2018-2028
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By End-User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.2. India
      • 7.2.5.3. Japan
      • 7.2.5.4. South Korea
      • 7.2.5.5. Australia
      • 7.2.5.6. Indonesia
      • 7.2.5.7. Singapore
      • 7.2.5.8. Malaysia
      • 7.2.5.9. Rest of Asia Pacific

8. Latin America Head and Neck Cancer Therapeutics Market

  • 8.1. Market Size & Forecast by Value, 2018-2028
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By End-User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.2. Mexico
      • 8.2.5.3. Argentina
      • 8.2.5.4. Rest of Latin America

9. The Middle East & Africa Head and Neck Cancer Therapeutics Market

  • 9.1. Market Size & Forecast by Value, 2018-2028
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.2. UAE
      • 9.2.5.3. South Africa
      • 9.2.5.4. Iran
      • 9.2.5.5. Nigeria
      • 9.2.5.6. Egypt
      • 9.2.5.7. Turkey
      • 9.2.5.8. Rest of Middle East & Africa

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Market Share Analysis, 2021
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Head and Neck Cancer Therapeutics Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, SWOT, and Strategic Outlook) **

  • 12.1. Pfizer INC
  • 12.2. Eli Lilly and Company
  • 12.3. Sun Pharmaceutical Industries Limited
  • 12.4. Intas Pharmaceuticals Ltd
  • 12.5. Glaxosmithkline PLC
  • 12.6. Novartis International AG
  • 12.7. Sanofi
  • 12.8. Bayer AG
  • 12.9. Hoffmann-LA Roche AG
  • 12.10. Merck & co., INC
  • 12.11. Astrazenica PLC
  • 12.12. Teva Pharmaceutical Industries Ltd.
  • 12.13. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents
  • 14.5. Assumptions & Limitations

Note: Financial in information in case of non-listed companies will be provided as per availability

The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List of Figures

  • Figure 1: Global Head and Neck Cancer Therapeutics Market Segmentation
  • Figure 2: Global Head and Neck Cancer Therapeutics Market Industry Value Chain Analysis
  • Figure 3: Global Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2018-2028
  • Figure 4: Global Head and Neck Cancer Therapeutics Market Share (%), By Type, By Value, 2018-2028
  • Figure 5: Global Head and Neck Cancer Therapeutics Market Share (%), By Treatment Type, By Value, 2018-2028
  • Figure 6: Global Head and Neck Cancer Therapeutics Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 7: Global Head and Neck Cancer Therapeutics Market Share (%), By End-User, By Value, 2018-2028
  • Figure 8: Global Head and Neck Cancer Therapeutics Market Share (%), By Region, By Value, 2018-2028
  • Figure 9: North America Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2018-2028
  • Figure 10: North America Head and Neck Cancer Therapeutics Market Share (%), By Type, By Value, 2018-2028
  • Figure 11: North America Head and Neck Cancer Therapeutics Market Share (%), By Treatment Type, By Value, 2018-2028
  • Figure 12: North America Head and Neck Cancer Therapeutics Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 13: North America Head and Neck Cancer Therapeutics Market Share (%), By End-User, By Value, 2018-2028
  • Figure 14: North America Head and Neck Cancer Therapeutics Market Share (%), By Country, By Value, 2018-2028
  • Figure 15: Europe Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2018-2028
  • Figure 16: Europe Head and Neck Cancer Therapeutics Market Share (%), By Type, By Value, 2018-2028
  • Figure 17: Europe Head and Neck Cancer Therapeutics Market Share (%), By Treatment Type, By Value, 2018-2028
  • Figure 18: Europe Head and Neck Cancer Therapeutics Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 19: Europe Head and Neck Cancer Therapeutics Market Share (%), By End-User, By Value, 2018-2028
  • Figure 20: Europe Head and Neck Cancer Therapeutics Market Share (%), By Country, By Value, 2018-2028
  • Figure 21: The Asia-Pacific Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2018-2028
  • Figure 22: The Asia-Pacific Head and Neck Cancer Therapeutics Market Share (%), By Type, By Value, 2018-2028
  • Figure 23: The Asia-Pacific Head and Neck Cancer Therapeutics Market Share (%), By Treatment Type, By Value, 2018-2028
  • Figure 24: The Asia-Pacific Head and Neck Cancer Therapeutics Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 25: The Asia-Pacific Head and Neck Cancer Therapeutics Market Share (%), By End-User, By Value, 2018-2028
  • Figure 26: The Asia-Pacific Head and Neck Cancer Therapeutics Market Share (%), By Country, By Value, 2018-2028
  • Figure 27: Latin America Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2018-2028
  • Figure 28: Latin America Head and Neck Cancer Therapeutics Market Share (%), By Type, By Value, 2018-2028
  • Figure 29: Latin America Head and Neck Cancer Therapeutics Market Share (%), By Treatment Type, By Value, 2018-2028
  • Figure 30: Latin America Head and Neck Cancer Therapeutics Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 31: Latin America Head and Neck Cancer Therapeutics Market Share (%), By End-User, By Value, 2018-2028
  • Figure 32: Latin America Head and Neck Cancer Therapeutics Market Share (%), By Country, By Value, 2018-2028
  • Figure 33: The Middle East & Africa Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2018-2028
  • Figure 34: The Middle East & Africa Head and Neck Cancer Therapeutics Market Share (%), By Type, By Value, 2018-2028
  • Figure 35: The Middle East & Africa Head and Neck Cancer Therapeutics Market Share (%), By Treatment Type, By Value, 2018-2028
  • Figure 36: The Middle East & Africa Head and Neck Cancer Therapeutics Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 37: The Middle East & Africa Head and Neck Cancer Therapeutics Market Share (%), By End-User, By Value, 2018-2028
  • Figure 38: The Middle East & Africa Head and Neck Cancer Therapeutics Market Share (%), By Country, By Value, 2018-2028
  • Figure 39: Global Head and Neck Cancer Therapeutics Market Share Analysis, 2021

List of Tables

  • Table 1: Global Head and Neck Cancer Therapeutics Market Size, By Type, By Value (USD Million), 2018-2028
  • Table 2: Global Head and Neck Cancer Therapeutics Market Size, By Treatment Type, By Value (USD Million), 2018-2028
  • Table 3: Global Head and Neck Cancer Therapeutics Market Size, By Route of Administration, By Value (USD Million), 2018-2028
  • Table 4: Global Head and Neck Cancer Therapeutics Market Size, By End-User, By Value (USD Million), 2018-2028
  • Table 5: Global Head and Neck Cancer Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028
  • Table 6: North America Head and Neck Cancer Therapeutics Market Size, By Type, By Value (USD Million), 2018-2028
  • Table 7: North America Head and Neck Cancer Therapeutics Market Size, By Treatment Type, By Value (USD Million), 2018-2028
  • Table 8: North America Head and Neck Cancer Therapeutics Market Size, By Route of Administration, By Value (USD Million), 2018-2028
  • Table 9: North America Head and Neck Cancer Therapeutics Market Size, By End-User, By Value (USD Million), 2018-2028
  • Table 10: North America Head and Neck Cancer Therapeutics Market Size (USD Million), By Country, By Value 2018-2028
  • Table 11: Europe Head and Neck Cancer Therapeutics Market Size, By Type, By Value (USD Million), By Value 2018-2028
  • Table 12: Europe Head and Neck Cancer Therapeutics Market Size, By Treatment Type, By Value (USD Million), By Value 2018-2028
  • Table 13: Europe Head and Neck Cancer Therapeutics Market Size, By Route of Administration, By Value (USD Million), By Value 2018-2028
  • Table 14: Europe Head and Neck Cancer Therapeutics Market Size, By End-User, By Value (USD Million), By Value 2018-2028
  • Table 15: 40 Europe Head and Neck Cancer Therapeutics Market Size (USD Million), By Country, By Value 2018-2028
  • Table 16: The Asia-Pacific Head and Neck Cancer Therapeutics Market Size, By Type, By Value (USD Million), By Value 2018-2028
  • Table 17: The Asia-Pacific Head and Neck Cancer Therapeutics Market Size (USD Million), By Type, By Value 2018-2028
  • Table 18: The Asia-Pacific Head and Neck Cancer Therapeutics Market Size (USD Million), By Treatment Type, By Value 2018-2028
  • Table 19: The Asia-Pacific Head and Neck Cancer Therapeutics Market Size (USD Million), By Route of Administration, By Value 2018-2028
  • Table 20: The Asia-Pacific Head and Neck Cancer Therapeutics Market Size (USD Million), By End-User, By Value 2018-2028
  • Table 21: The Asia-Pacific Head and Neck Cancer Therapeutics Market Size (USD Million), By Country, By Value 2018-2028
  • Table 22: Latin America Head and Neck Cancer Therapeutics Market Size, By Type, By Value (USD Million), By Value 2018-2028
  • Table 23: Latin America Head and Neck Cancer Therapeutics Market Size, By Treatment Type, By Value (USD Million), 2018-2028
  • Table 24: Latin America Head and Neck Cancer Therapeutics Market Size, By Route of Administration, By Value (USD Million), 2018-2028
  • Table 25: Latin America Head and Neck Cancer Therapeutics Market Size, By End-User, By Value (USD Million), 2018-2028
  • Table 26: Latin America Head and Neck Cancer Therapeutics Market Size (USD Million), By Country, By Value 2018-2028
  • Table 27: The Middle East & Africa Head and Neck Cancer Therapeutics Market Size, By Type, By Value (USD Million), 2018-2028
  • Table 28: The Middle East & Africa Head and Neck Cancer Therapeutics Market Size, By Treatment Type, By Value (USD Million), 2018-2028
  • Table 29: The Middle East & Africa Head and Neck Cancer Therapeutics Market Size, By Route of Administration, By Value (USD Million), 2018-2028
  • Table 30: The Middle East & Africa Head and Neck Cancer Therapeutics Market Size, By End-User, By Value (USD Million), 2018-2028
  • Table 31: The Middle East & Africa Head and Neck Cancer Therapeutics Market Size (USD Million), By Country, By Value 2018-2028
  • Table 32: List of Key Players and Their Offerings
  • Table 33: Competitive Benchmarking, by Operating Parameters
  • Table 34 Pfizer INC Company Overview
  • Table 35 Pfizer INC Financial Overview
  • Table 36 Lilly Company Overview
  • Table 37 Lilly Financial Overview
  • Table 38 Sun Pharmaceutical Industries Limited Company Overview
  • Table 39 Sun Pharmaceutical Industries Limited Financial Overview
  • Table 40 Intas Pharmaceuticals Ltd Company Overview
  • Table 41 Intas Pharmaceuticals Ltd Financial Overview
  • Table 42 Glaxosmithkline PLC Company Overview
  • Table 43 Glaxosmithkline PLC Financial Overview
  • Table 44 Novartis International AG Company Overview
  • Table 45 Novartis International Financial Overview
  • Table 46 Sanofi Company Overview
  • Table 47 Sanofi Financial Overview
  • Table 48 Bayer AG Company Overview
  • Table 49 Bayer AG Financial Overview
  • Table 50 Hoffmann -LA Roche AG Company Overview
  • Table 51 Hoffmann -LA Roche AG Financial Overview
  • Table 52 Merck & Co., INC Company Overview
  • Table 53 Merck & Co., INC Financial Overview
  • Table 54 Astrazenica PLC Company Overview
  • Table 55 Astrazenica PLC Financial Overview
  • Table 56 Teva Pharmaceutical Industries LTD Company Overview
  • Table 57 Teva Pharmaceutical Industries LTD Financial Overview